NCT05361772 (COIN) is a NA clinical trial of colchicine in Colchicine, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT05361772?

NCT05361772 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT05361772?

Interventions in NCT05361772: colchicine, Placebo.

What condition does NCT05361772 study?

NCT05361772 studies Colchicine, Abdominal Aortic Aneurysm, Progression.

Is NCT05361772 still recruiting?

NCT05361772 is currently status unknown. Last updated 5 May 2022.

Last reviewed 2022-05-05 · How we verify

NCT05361772: COIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial

Status unknown NA Last updated 5 May 2022

What this trial tests

NA trial testing colchicine in Colchicine in 230 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 June 2024

31 December 2025

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	230
Start date	1 June 2022
Primary completion	1 June 2024
Estimated completion	31 December 2025

Drugs / interventions tested

colchicine (COLCHICINE) — full drug profile →
Placebo

Conditions studied

Colchicine — all drugs for Colchicine →
Abdominal Aortic Aneurysm — all drugs for Abdominal Aortic Aneurysm →
Progression — all drugs for Progression →

Sponsor

Guangdong Provincial People's Hospital

Who can join

Adults 55 to 85, any sex, with Colchicine or Abdominal Aortic Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COIN trial is a a prospective, randomized, placebo-controlled, double-blind, multicenter clinical study. Approximately 230 patients with small abdominal aortic aneurysms (AAA) will be randomly allocated to low-dose colchicine group or placebo group. All study patients will be followed up in the outpatient clinic every 3 months and undergo CTA scans after 24 months from randomization. The primary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA diameter. The secondary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA volume, reduce the incidence of clinical outcomes associated with AAA, reduce the incidence of major adverse cardiovascular events and all-cause mortality.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.
Wang X, Chen L, Wei J, Zheng H, et al · · 2025 · cited 39× · PMID 40404619 · DOI 10.1038/s41392-025-02220-z
Colchicine Blocks Abdominal Aortic Aneurysm Development by Maintaining Vascular Smooth Muscle Cell Homeostasis.
Chen M, Yang D, Zhou Y, Yang C, et al · · 2024 · cited 20× · PMID 38617538 · DOI 10.7150/ijbs.93544
Recent Advances in Nanomedicine-Mediated Abdominal Aortic Aneurysm Treatment.
Lu X, Hu Q. · · 2025 · cited 5× · PMID 40384281 · DOI 10.1002/smtd.202402268

Verify or expand the search:

Other trials of colchicine

Trials testing the same drug.

NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
NCT07280572 — RECLAIM Adaptive Platform Trial for PCC Treatments · Phase 3 · enrolling by invitation
NCT03226899 — A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment · Phase 4 · terminated
NCT02551094 — Colchicine Cardiovascular Outcomes Trial (COLCOT) · Phase 3 · completed

Other recruiting trials for Colchicine

Currently open trials in the same condition.

NCT06798714 — The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery · Phase 4 · recruiting
NCT06472908 — Efficacy and Safety of Colchicine After PCI · Phase 3 · recruiting
NCT05637398 — Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction · Phase 1, PHASE2 · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05361772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 5 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing